HR 6679

Tim Fagan's Law

Congress: 112 (2011–2013, Ended)
Chamber: House
Policy Area: Health
Introduced: Dec 18, 2012
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Dec 19, 2012)
Official Text: https://www.congress.gov/bill/112th-congress/house-bill/6679

Sponsor

Name: Rep. Israel, Steve [D-NY-2]
Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 19, 2012

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 18, 2012)

Tim Fagan's Law or Counterfeit Drug Enforcement Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act to establish a criminal fine and/or imprisonment for a person who: (1) knowingly causes a prescription drug to be adulterated, misbranded, or misrepresented as an approved prescription drug and sells or trades the drug; or (2) purchases or trades for such drug knowing or having reason to know that the drug was knowingly adulterated, misbranded, or misrepresented. Requires a manufacturer of a drug to notify the Secretary of Health and Human Services (HHS) within 48 hours after first receiving or becoming aware of information that reasonably suggests that such a violation may have occurred.

Deems a drug to be misbranded if it is not manufactured in accordance with the use of technologies that the Secretary determines are technically feasible and will assist in preventing such violations.

Requires the Secretary to establish alternative requirements to the extent that such requirements provide greater certainty on the chain of custody and are technically feasible.

Increases funding for Food and Drug Administration (FDA) inspections, examinations, and investigations.

Requires the Secretary to educate the public and health care professionals on counterfeit drugs.

Directs the Secretary: (1) upon a finding that a drug intended for human use may constitute a threat to the public health to issue an order requiring the appropriate person (including the manufacturers, importers, distributors, or retailers of the drug) to cease distribution of the drug and to notify and instruct health professionals to cease administering, distributing, selling, or prescribing the drug; and (2) amend the order to include a recall if necessary.

Actions Timeline

- **Dec 19, 2012:** Referred to the Subcommittee on Health.
- **Dec 18, 2012:** Introduced in House
- **Dec 18, 2012:** Referred to the House Committee on Energy and Commerce.